<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28857388</article-id><article-id pub-id-type="pmc">5813139</article-id><article-id pub-id-type="doi">10.1111/dom.13104</article-id><article-id pub-id-type="publisher-id">DOM13104</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Metformin extended&#x02010;release versus immediate&#x02010;release: <styled-content style="fixed-case">A</styled-content>n international, randomized, double&#x02010;blind, head&#x02010;to&#x02010;head trial in pharmacotherapy&#x02010;na&#x000ef;ve patients with type 2 diabetes</article-title><alt-title alt-title-type="left-running-head">Aggarwal et al.</alt-title></title-group><contrib-group><contrib id="dom13104-cr-0001" contrib-type="author" corresp="yes"><name><surname>Aggarwal</surname><given-names>Naresh</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7111-0184</contrib-id><address><email>naresh.aggarwal@aaaresearch.ca</email></address><xref ref-type="aff" rid="dom13104-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13104-cr-0002" contrib-type="author"><name><surname>Singla</surname><given-names>Anuj</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13104-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13104-cr-0003" contrib-type="author"><name><surname>Mathieu</surname><given-names>Chantal</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13104-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13104-cr-0004" contrib-type="author"><name><surname>Montanya</surname><given-names>Eduard</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13104-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13104-cr-0005" contrib-type="author"><name><surname>Pfeiffer</surname><given-names>Andreas F. H.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13104-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13104-cr-0006" contrib-type="author"><name><surname>Johnsson</surname><given-names>Eva</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13104-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom13104-cr-0007" contrib-type="author"><name><surname>Zhao</surname><given-names>June</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom13104-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom13104-cr-0008" contrib-type="author"><name><surname>Iqbal</surname><given-names>Nayyar</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13104-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom13104-cr-0009" contrib-type="author"><name><surname>Bailey</surname><given-names>Clifford</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13104-aff-0007">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="dom13104-aff-0001" content-type="private-address">
<label><sup>1</sup></label>
<institution>AAA Clinical Research</institution>
<named-content content-type="city">Brampton</named-content>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="dom13104-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Endocrinology</named-content>
<institution>Katholieke Universiteit Leuven</institution>
<named-content content-type="city">Leuven</named-content>
<country country="BE">Belgium</country>
</aff><aff id="dom13104-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<institution>Department of Endocrinology, Bellvitge University Hospital&#x02010;IDIBELL, CIBERDEM, University of Barcelona</institution>
<named-content content-type="city">Barcelona</named-content>
<country country="ES">Spain</country>
</aff><aff id="dom13104-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Endocrinology, Diabetes and Nutrition</named-content>
<institution>Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin</institution>
<named-content content-type="city">Berlin</named-content>
<country country="DE">Germany</country>
</aff><aff id="dom13104-aff-0005" content-type="private-address">
<label><sup>5</sup></label>
<institution>AstraZeneca Gothenburg</institution>
<named-content content-type="city">M&#x000f6;lndal</named-content>
<country country="SE">Sweden</country>
</aff><aff id="dom13104-aff-0006" content-type="private-address">
<label><sup>6</sup></label>
<institution>AstraZeneca</institution>
<named-content content-type="city">Gaithersburg</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><aff id="dom13104-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">School of Life and Health Sciences</named-content>
<institution>Aston University</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Naresh Aggarwal MD, CCFP, FCFP,AAA Clinical Research, 490 Bramalea Rd, Unit 201, Brampton, ON L6T 0G1, Canada. Email: <email>naresh.aggarwal@aaaresearch.ca</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><volume>20</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-2</issue-id><fpage>463</fpage><lpage>467</lpage><history><date date-type="received"><day>23</day><month>6</month><year>2017</year></date><date date-type="rev-recd"><day>15</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-463.pdf"/><abstract><p>This international, randomized, double&#x02010;blind trial (NCT01864174) compared the efficacy and safety of metformin extended&#x02010;release (XR) and immediate&#x02010;release (IR) in patients with type 2 diabetes. After a 4&#x02010;week placebo lead&#x02010;in, pharmacotherapy&#x02010;na&#x000ef;ve adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once&#x02010;daily metformin XR 2000&#x02009;mg or twice&#x02010;daily metformin IR 1000&#x02009;mg for 24&#x02009;weeks. The primary endpoint was change in HbA1c after 24&#x02009;weeks. Secondary endpoints were change in fasting plasma glucose (FPG), mean daily glucose (MDG) and patients (%) with HbA1c &#x0003c;7.0% after 24&#x02009;weeks. Overall, 539 patients were randomized (metformin XR, N&#x02009;=&#x02009;268; metformin IR, N&#x02009;=&#x02009;271). Adjusted mean changes in HbA1c, FPG, MDG and patients (%) with HbA1c &#x0003c;7.0% after 24&#x02009;weeks were similar for XR and IR: &#x02212;0.93% vs &#x02212;0.96%; &#x02212;21.1 vs &#x02212;20.6&#x02009;mg/dL (&#x02212;1.2 vs &#x02212;1.1&#x02009;mmol/L); &#x02212;24.7 vs &#x02212;27.1&#x02009;mg/dL (&#x02212;1.4 vs &#x02212;1.5&#x02009;mmol/L); and 70.9% vs 72.0%, respectively. Adverse events were similar between groups and consistent with previous studies. Overall, metformin XR demonstrated efficacy and safety similar to that of metformin IR over 24&#x02009;weeks, with the advantage of once&#x02010;daily dosing.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13104-kwd-0001">glycated haemoglobin</kwd><kwd id="dom13104-kwd-0002">metformin extended&#x02010;release</kwd><kwd id="dom13104-kwd-0003">once&#x02010;daily dosing</kwd><kwd id="dom13104-kwd-0004">randomized clinical trial</kwd><kwd id="dom13104-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="5"/><word-count count="3270"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13104</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:15.02.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom13104-cit-9001">
<string-name>
<surname>Aggarwal</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Singla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mathieu</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Metformin extended&#x02010;release versus immediate&#x02010;release: <styled-content style="fixed-case">A</styled-content>n international, randomized, double&#x02010;blind, head&#x02010;to&#x02010;head trial in pharmacotherapy&#x02010;na&#x000ef;ve patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2018</year>;<volume>20</volume>:<fpage>463</fpage>&#x02013;<lpage>467</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13104">https://doi.org/10.1111/dom.13104</ext-link>
<pub-id pub-id-type="pmid">28857388</pub-id></mixed-citation>
</p><fn-group><fn id="dom13104-note-0002a"><p>
<bold>Funding information</bold>
</p><p>This study was funded by AstraZeneca.</p></fn></fn-group></notes></front><body><sec id="dom13104-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Metformin, a first&#x02010;line treatment for patients with type 2 diabetes, is available as an immediate&#x02010;release (IR) formulation, typically administered several times daily with meals, and an extended&#x02010;release (XR) formulation, administered once daily.<xref rid="dom13104-bib-0001" ref-type="ref">1</xref>, <xref rid="dom13104-bib-0002" ref-type="ref">2</xref>, <xref rid="dom13104-bib-0003" ref-type="ref">3</xref>, <xref rid="dom13104-bib-0004" ref-type="ref">4</xref>, <xref rid="dom13104-bib-0005" ref-type="ref">5</xref>, <xref rid="dom13104-bib-0006" ref-type="ref">6</xref> The pharmacokinetic properties of metformin IR are generally comparable to those of the XR formulation.<xref rid="dom13104-bib-0007" ref-type="ref">7</xref> However, peak plasma concentrations (C<sub>max</sub>) for metformin IR occur ~3&#x02009;hours after a single oral 1000&#x02010;mg dose (mean C<sub>max</sub> [standard deviation (SD)], 1321 [234] ng/mL), whereas peak plasma concentrations of metformin XR 2000&#x02009;mg occur within 7 to 8&#x02009;hours after dosing (mean C<sub>max</sub> [SD], 1780 [288] ng/mL).<xref rid="dom13104-bib-0007" ref-type="ref">7</xref> Both formulations are well tolerated and are effective in reducing glycated haemoglobin (HbA1c) levels as compared to placebo in patients with type 2 diabetes.<xref rid="dom13104-bib-0008" ref-type="ref">8</xref>, <xref rid="dom13104-bib-0009" ref-type="ref">9</xref> Previous studies have shown greater patient adherence<xref rid="dom13104-bib-0010" ref-type="ref">10</xref>, <xref rid="dom13104-bib-0011" ref-type="ref">11</xref> and indicate improved gastrointestinal (GI) tolerability with metformin XR compared with metformin IR.<xref rid="dom13104-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13104-bib-0012" ref-type="ref">12</xref>, <xref rid="dom13104-bib-0013" ref-type="ref">13</xref>
</p><p>Despite widespread use of both metformin IR and XR preparations, only 2 head&#x02010;to&#x02010;head clinical trials comparing the safety and efficacy of metformin IR and metformin XR have been conducted, one in the USA and the other in China.<xref rid="dom13104-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13104-bib-0012" ref-type="ref">12</xref> However, both studies included patients who had previously received metformin.<xref rid="dom13104-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13104-bib-0012" ref-type="ref">12</xref> The Chinese study had an open&#x02010;label design, comprising a relatively small number of patients and comparing the 2 metformin formulations at 1500&#x02009;mg/d over 12&#x02009;weeks.<xref rid="dom13104-bib-0011" ref-type="ref">11</xref> The US study was larger and of a longer duration than the Chinese study and compared metformin XR (at different dosages) with metformin IR at a dose of 1500&#x02009;mg/d. In the US study, patients previously treated with metformin and a sulphonylurea were permitted.<xref rid="dom13104-bib-0012" ref-type="ref">12</xref> The aim of this trial was to evaluate the efficacy, safety and tolerability of the same 2000&#x02009;mg daily doses of once&#x02010;daily metformin XR versus twice&#x02010;daily metformin IR in pharmacotherapy&#x02010;na&#x000ef;ve patients with type 2 diabetes.</p></sec><sec id="dom13104-sec-0002"><label>2</label><title>METHODS</title><sec id="dom13104-sec-0003"><label>2.1</label><title>Study design</title><p>This was an international, randomized, parallel&#x02010;group, double&#x02010;blind trial (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01864174) conducted at 148 sites (June 2013 to June 2016) in North America (USA, Canada, Puerto Rico), Europe (Czech Republic, Germany, Hungary, Poland, Romania, UK) and South Africa. Eligible patients entered a 4&#x02010;week, single&#x02010;blind, placebo lead&#x02010;in period, followed by a 24&#x02010;week, randomized, double&#x02010;blind treatment period. Patients were randomized (1:1) to receive either once&#x02010;daily metformin XR (Glucophage&#x000ae; XR, Bristol&#x02010;Myers Squibb) 2000&#x02009;mg (with evening meals) or twice&#x02010;daily metformin IR (Glucophage&#x000ae;, Bristol&#x02010;Myers Squibb) 1000&#x02009;mg (every morning and evening with meals) for 24&#x02009;weeks. During the double&#x02010;blind treatment period, metformin XR and IR were titrated from 500 to 2000&#x02009;mg/d over the first 3&#x02009;weeks of treatment. Patients who were unable to tolerate 2000&#x02009;mg/d were down&#x02010;titrated and re&#x02010;challenge was attempted, if possible, before week 12. The study was conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonisation, and the study protocol was approved by the Institutional Review Board/Independent Ethics Committee at each participating institution.</p></sec><sec id="dom13104-sec-0004"><label>2.2</label><title>Patients</title><p>Patients (&#x02265;18&#x02009;years old) who had type 2 diabetes and inadequate glycaemic control with diet and lifestyle advice alone (ie, pharmacotherapy&#x02010;na&#x000ef;ve, defined as no prior pharmacotherapy for glucose lowering within 90&#x02009;days prior to enrolment and no more than 14&#x02009;days of glucose&#x02010;lowering medication) were eligible for inclusion. Key inclusion criteria were: HbA1c, 7.0% to 9.2% at screening; body mass index (BMI) &#x02264;45.0&#x02009;kg/m<sup>2</sup>; fasting plasma glucose (FPG) &#x0003c;250&#x02009;mg/dL (13.9&#x02009;mmol/L); C&#x02010;peptide &#x02265;1.0&#x02009;ng/mL at enrolment. Key exclusion criteria were: history of ketoacidosis, lactic acidosis or hyperosmolar non&#x02010;ketotic coma; marked polyuria; polydipsia with &#x0003e;10% weight loss during last 3&#x02009;months prior to screening/enrolment; and elevated serum creatinine levels. Patients provided written informed consent before participating in the study, which followed the ethical principles of the Declaration of Helsinki.</p></sec><sec id="dom13104-sec-0005"><label>2.3</label><title>Study assessments</title><p>The primary efficacy endpoint was mean change in HbA1c from baseline to week 24, which was also examined by baseline HbA1c subgroup (&#x0003c;8%, &#x02265;8 to &#x0003c;9% and &#x02265;9%). The secondary efficacy endpoints were mean change in FPG and mean daily glucose (MDG) levels from baseline to week 24 (or last observation carried forward [LOCF] for MDG) and percentage of patients achieving a therapeutic glycaemic response (HbA1c &#x0003c;7.0%) at week 24. MDG was self&#x02010;monitored using a 7&#x02010;point fingerstick blood&#x02010;glucose test. Mean change in body weight and waist circumference, and mean percentage change in fasting serum lipids from baseline to week 24 were also assessed. Safety assessments included incidence of adverse events (AEs), clinical laboratory evaluations (haematology, blood chemistry, liver function tests, urinalysis) and vital signs. Hypoglycaemia was also assessed; all episodes consistent with the clinical definition of hypoglycemia as assessed by the investigator were documented. Reasons for discontinuation because of hypoglycaemia included, but were not limited to, a documented fingerstick glucose value &#x02264;54&#x02009;mg/dL (&#x02264;3.1&#x02009;mmol/L).</p></sec><sec id="dom13104-sec-0006"><label>2.4</label><title>Statistical analyses</title><p>Given a sample size of 235 patients/group, the study would provide 90% power to demonstrate non&#x02010;inferiority in change from baseline to week 24 in mean HbA1c (assumed SD, 1.0%; non&#x02010;inferiority margin, 0.3%; 2&#x02010;sided &#x003b1;&#x02009;=&#x02009;0.05). Assuming that approximately 10% of patients would not have a post&#x02010;baseline value, approximately 524 patients would be required for randomization.</p><p>The primary efficacy endpoint was analysed using a longitudinal repeated&#x02010;measures model, which adjusted for baseline HbA1c, treatment group, time, baseline&#x02010;by&#x02010;time interaction and time&#x02010;by&#x02010;treatment group interaction. Changes in FPG were assessed using the same model. For MDG, changes from baseline to week 24/LOCF were analysed using an analysis of covariance (ANCOVA) model. For the percentage of patients with HbA1c &#x0003c;7.0% at week 24, data were analysed using logistic regression,<xref rid="dom13104-bib-0014" ref-type="ref">14</xref>, <xref rid="dom13104-bib-0015" ref-type="ref">15</xref> with adjustments for baseline HbA1c. These analyses were performed using data from patients who received at least 1 dose of double&#x02010;blind study drug during the randomized treatment period (randomized data set). Values prior to initiation of rescue medication were used for analysis of these data. The treated data set includes all patients who received at least 1 dose of double&#x02010;blind study drug during the treatment period, regardless of rescue.</p></sec></sec><sec id="dom13104-sec-0007"><label>3</label><title>RESULTS</title><sec id="dom13104-sec-0008"><label>3.1</label><title>Patient disposition and baseline characteristics</title><p>Of the 1736 patients enroled, 794 (45.7%) were eligible to enter the placebo lead&#x02010;in period, of whom 568 patients were randomized (1:1) to receive either once&#x02010;daily metformin XR (N&#x02009;=&#x02009;283) or twice&#x02010;daily metformin IR (N&#x02009;=&#x02009;285) (Figure <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S1</xref>). The most common reason for study non&#x02010;eligibility or non&#x02010;randomization was no longer meeting study criteria (Figure <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S1</xref>). Of those patients who were randomized, 29 were excluded because of study site non&#x02010;compliance. Thus, the randomized data set became metformin XR (N&#x02009;=&#x02009;268) and metformin IR (N&#x02009;=&#x02009;271). Overall, 245 patients in both groups completed the double&#x02010;blind period of the study. Baseline demographics and disease characteristics are shown in Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="dom13104-sec-0009"><label>3.2</label><title>Extent of exposure</title><p>Patients receiving once&#x02010;daily metformin XR and twice&#x02010;daily metformin IR had similar exposure and total daily doses of study drug (Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S2</xref>). Down&#x02010;titration because of metformin intolerance was implemented in 37 and 108 patients receiving metformin XR and IR, respectively. However, for patients who were down&#x02010;titrated, up&#x02010;titrations/rechallenges with higher doses were attempted before week 12. Eight patients received rescue medication (metformin XR, n&#x02009;=&#x02009;3; metformin IR, n&#x02009;=&#x02009;5) (Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S2</xref>).</p></sec><sec id="dom13104-sec-0010"><label>3.3</label><title>Efficacy</title><p>Baseline mean (standard deviation) HbA1c was 7.58% (0.6) for metformin XR and 7.76% (0.5) for metformin IR. The adjusted mean change (standard error [SE]) in HbA1c from baseline to week 24 was similar between treatment arms (metformin XR, &#x02212;0.93% [0.05]; metformin IR, &#x02212;0.96% [0.05]), resulting in a non&#x02010;significant difference of 0.03% between groups (95% confidence interval, &#x02212;0.10 to 0.17) (Figure <xref rid="dom13104-fig-0001" ref-type="fig">1</xref>). A subgroup analysis using baseline HbA1c supported this finding (Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S3</xref>). Baseline adjusted changes in mean (SE) FPG and MDG levels, and percentage of patients with HbA1c &#x0003c;7.0% at week 24/LOCF were similar between treatment arms (Table <xref rid="dom13104-tbl-0001" ref-type="table-wrap">1</xref>), as were changes in body weight, waist circumference and serum lipid profiles (Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S4</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom13104-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Adjusted<sup>a</sup> mean change (SE) in HbA1c (%) from baseline to week 24 for patients receiving twice&#x02010;daily metformin IR or once&#x02010;daily metformin XR (randomized data set)<sup>b</sup>. <sup>a</sup>Adjusted for baseline HbA1c, treatment group, time, baseline&#x02010;by&#x02010;time interaction and time&#x02010;by&#x02010;treatment group interaction and <sup>b</sup>excluding data after rescue medication. Abbreviations: HbA1c, glycated haemoglobin; IR, immediate release; SE, standard error; XR, extended release</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-463-g001"/></fig><table-wrap id="dom13104-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Adjusted mean changes in secondary efficacy endpoints from baseline to week 24 (randomized data set)<xref ref-type="fn" rid="dom13104-note-0005">a</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="middle"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="middle" rowspan="1" colspan="1">Secondary efficacy endpoint</th><th align="left" valign="middle" rowspan="1" colspan="1">Metformin XR<break/>
2000&#x02009;mg QD<break/>
(N&#x02009;=&#x02009;268)
</th><th align="left" valign="middle" rowspan="1" colspan="1">Metformin IR<break/>
1000&#x02009;mg BID<break/>
(N&#x02009;=&#x02009;271)
</th><th align="left" valign="middle" rowspan="1" colspan="1">Difference<break/>
(95% CI)
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>FPG, mg/dL</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline, mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">153.8 (30.7)</td><td align="left" valign="top" rowspan="1" colspan="1">157.9 (33.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 24, mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">131.9 (31.2)</td><td align="left" valign="top" rowspan="1" colspan="1">134.9 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adj mean change from baseline (SE)<xref ref-type="fn" rid="dom13104-note-0006">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;228</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;229</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;21.1 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;20.6 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;5.5 to 4.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>MDG, mg/dL</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline, mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">161.4 (29.8)</td><td align="left" valign="top" rowspan="1" colspan="1">169.9 (31.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 24 (LOCF), mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">139.3 (26.2)</td><td align="left" valign="top" rowspan="1" colspan="1">140.4 (26.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adj mean change from baseline (SE)<xref ref-type="fn" rid="dom13104-note-0007">c</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;211</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;218</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;24.7 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;27.1 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (&#x02212;2.0 to 6.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Patients achieving HbA1c &#x0003c;7.0%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 24, patients (%)</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;237</td><td align="left" valign="top" rowspan="1" colspan="1">n&#x02009;=&#x02009;237</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">174 (73.4)</td><td align="left" valign="top" rowspan="1" colspan="1">166 (70.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Week 24, adjusted % (SE)</td><td align="left" valign="top" rowspan="1" colspan="1">70.9 (2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">72.0 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;8.7 to 6.5)</td></tr></tbody></table><table-wrap-foot><fn id="dom13104-note-0002"><p>Abbreviations: Adj, adjusted; BID, twice daily; CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IR, immediate release; LOCF, last observation carried forward; MDG, mean daily glucose; QD, once daily; SD, standard deviation; SE, standard error; XR, extended release.</p></fn><fn id="dom13104-note-0003"><p>n values are number of randomized patients who had non&#x02010;missing baseline values and values at week 24.</p></fn><fn id="dom13104-note-0004"><p>Data are adjusted mean changes from baseline, except for the responder rate (reported as percentage of patients achieving HbA1c &#x0003c;7.0% at week 24; percentage adjusted for baseline HbA1c).</p></fn><fn id="dom13104-note-0005"><label>a</label><p>Excluding data after rescue medication.</p></fn><fn id="dom13104-note-0006"><label>b</label><p>Metformin XR vs metformin IR, &#x02212;1.2 vs &#x02212;1.1&#x02009;mmol/L.</p></fn><fn id="dom13104-note-0007"><label>c</label><p>Metformin XR vs metformin IR, &#x02212;1.4 vs &#x02212;1.5&#x02009;mmol/L.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom13104-sec-0011"><label>3.4</label><title>Safety and tolerability</title><p>Overall, 50.2% (142/283) and 47.4% (135/285) of patients in the metformin XR and IR groups reported at least 1 treatment&#x02010;emergent AE, respectively (Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S5</xref>). Of these, 10.6% and 8.8% were considered treatment&#x02010;related, respectively. Serious AEs (SAEs) were reported for 2.8% (8/283) and 3.5% (10/285) of patients receiving metformin XR and IR, respectively; only 1 case per group was considered treatment&#x02010;related. The most common reason for discontinuation because of AEs was GI disorders (metformin XR, 1.4%; metformin IR, 1.4%). The most frequently reported AEs were GI in nature, ie, diarrhoea, nausea and vomiting (Table <xref rid="dom13104-supitem-0001" ref-type="supplementary-material">S5</xref>). There were no clinically meaningful changes in vital signs or standard laboratory variables, including creatinine, hepatic panel and urinalysis parameters.</p></sec><sec id="dom13104-sec-0012"><label>3.5</label><title>Hypoglycaemia</title><p>After 24&#x02009;weeks of treatment, no hypoglycaemia events were reported in patients receiving once&#x02010;daily metformin XR compared with 3 patients (1.1%) receiving twice&#x02010;daily metformin IR. There were 5 events in total: 2 classified as &#x0201c;probable symptomatic hypoglycaemia&#x0201d; and 3 as &#x0201c;relative hypoglycaemia&#x0201d; (according to American Diabetes Association recommendations).</p></sec></sec><sec id="dom13104-sec-0013"><label>4</label><title>DISCUSSION</title><p>Few head&#x02010;to&#x02010;head trials have been conducted to establish therapeutic equivalency of metformin IR and XR formulations.<xref rid="dom13104-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13104-bib-0012" ref-type="ref">12</xref> We report an international, 24&#x02010;week, head&#x02010;to&#x02010;head trial of metformin XR and IR conducted in pharmacotherapy&#x02010;na&#x000ef;ve patients with type 2 diabetes. The results demonstrate that once&#x02010;daily metformin XR 2000&#x02009;mg and twice&#x02010;daily metformin IR 1000&#x02009;mg monotherapy have similar efficacy and safety profiles.</p><p>The primary efficacy endpoint demonstrated the non&#x02010;inferiority of metformin XR compared with metformin IR, which was confirmed in subgroup analysis by baseline HbA1c. Results from the 3 secondary efficacy endpoints, change from baseline to week 24 in FPG and MDG and proportion of patients achieving a therapeutic glycaemic response of HbA1c &#x0003c;7.0% at week 24, supported this finding. In the previously reported 24&#x02010;week head&#x02010;to&#x02010;head study,<xref rid="dom13104-bib-0012" ref-type="ref">12</xref> the mean decrease in HbA1c from baseline to week 24 for once&#x02010;daily metformin XR 2000&#x02009;mg was &#x02212;1.06%, similar to the value reported in this study. Patients in the metformin IR group received a lower dose than was used here (500&#x02009;mg in the morning and 1000&#x02009;mg in the evening vs 1000&#x02009;mg twice daily) and experienced a mean decrease in HbA1c of &#x02212;0.70%.</p><p>Once&#x02010;daily metformin XR and twice&#x02010;daily metformin IR were well tolerated, as reported in the literature<xref rid="dom13104-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13104-bib-0012" ref-type="ref">12</xref> and product labelling.<xref rid="dom13104-bib-0001" ref-type="ref">1</xref> Notably, the most common AE was diarrhoea in both treatment groups. The frequency of nausea was slightly higher with metformin XR than with metformin IR (4.6% vs 2.8%, respectively), which contrasts with the previous head&#x02010;to&#x02010;head trials<xref rid="dom13104-bib-0011" ref-type="ref">11</xref>, <xref rid="dom13104-bib-0012" ref-type="ref">12</xref>; however, overall, nausea was reported by few patients in both groups. Moreover, AEs and SAEs leading to study discontinuation were reported for fewer than 5% of patients in both treatment groups.</p><p>In this study, down&#x02010;titration because of metformin intolerance<xref rid="dom13104-bib-0001" ref-type="ref">1</xref> was necessary in almost 3 times as many patients treated with metformin IR compared with metformin XR. The reduced requirement for down&#x02010;titration from 2000&#x02009;mg/d with metformin XR, in addition to the once&#x02010;daily dosing regimen, may help to improve the patient and physician experience. Patients in this study were highly selected (a large proportion of patients did not meet the study criteria) and were motivated to comply with medication; however, outside of a controlled study setting, the potential patient compliance benefits of once&#x02010;daily vs twice&#x02010;daily dosing are more likely to become apparent.</p><p>In conclusion, this international head&#x02010;to&#x02010;head trial has demonstrated the therapeutic equivalence of metformin XR and metformin IR over a 24&#x02010;week period in pharmacotherapy&#x02010;na&#x000ef;ve patients with type 2 diabetes, and confirms metformin XR as an important treatment option for patients in whom dosing frequency could affect medication compliance and compromise treatment outcomes.</p></sec><sec id="dom13104-sec-0016a"><title>ORCID</title><p>
<italic>Naresh Aggarwal</italic>
<ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-7111-0184">http://orcid.org/0000&#x02010;0001&#x02010;7111&#x02010;0184</ext-link>
</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13104-supitem-0001"><caption><p>
<bold>Figure S1.</bold> Patient disposition.</p><p>
<bold>Table S1.</bold> Demographic and disease characteristics at baseline (randomized data set)</p><p>
<bold>Table S2.</bold> Extent of exposure (treated data set).</p><p>
<bold>Table S3.</bold> Subgroup analysis for the primary endpoint using baseline HbA1c categories (randomized data set).</p><p>
<bold>Table S4.</bold> Mean changes in other efficacy endpoints from baseline to week 24 (randomized data set).</p><p>
<bold>Table S5.</bold> Summary of adverse events (treated data set).</p></caption><media xlink:href="DOM-20-463-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13104-sec-0014"><title>ACKNOWLEDGEMENTS</title><p>The authors thank all study participants and investigators. Medical writing support was provided by Luci Witcomb, PhD and Sarah Graham, PhD of PharmaGenesis London, London, UK, with funding from AstraZeneca.</p><sec id="dom13104-sec-0015" sec-type="COI-statement"><title>Conflict of interests</title><p>N. A. and A. S. report no conflicts of interest. C. M. reports advisory/consultancy activities for AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Eli Lilly &#x00026; Company, Novartis AG, Hanmi Pharmaceutical, Intrexon, Janssen Pharmaceutical, MannKind Corporation, Medtronic, Merck Sharp &#x00026; Dohme, Novo Nordisk, Sanofi, Pfizer, Roche Diagnostics and UCB Pharma; speaker's bureau activities for AstraZeneca, Boehringer Ingelheim, Eli Lilly &#x00026; Company, Merck Sharp &#x00026; Dohme, Novartis AG, Novo Nordisk and Sanofi; and has received research support from Abbott, Eli Lilly &#x00026; Company, Intrexon, Merck Sharp &#x00026; Dohme, Novartis AG, Novo Nordisk, Roche Diagnostics and Sanofi. E. M. reports advisory/consultancy activities for AstraZeneca, Boehringer Ingelheim, Eli Lilly &#x00026; Company, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceutical, Laboratoires Servier, Merck Sharp &#x00026; Dohme, Novo Nordisk and Sanofi. A. F. H. P. reports advisory/consultancy activities for AstraZeneca, Berlin&#x02010;Chemie, Novo Nordisk, Eli Lilly &#x00026; Company and Sanofi. J. Z., E. J. and N. I. are employees and stockholders of AstraZeneca. C.B. reports advisory/consultancy activities for Abbott Laboratories, AstraZeneca, Bristol&#x02010;Myers Squibb, Boehringer Ingelheim, Elcelyx, Eli Lilly &#x00026; Company, Johnson &#x00026; Johnson, Merck Sharp &#x00026; Dohme, Novo Nordisk, Poxel and Sanofi.</p></sec><sec id="dom13104-sec-0016"><title>Author contributions</title><p>All authors fulfill the authorship criteria of the International Committee of Medical Journal Editors by substantial contribution to the conception and design, to acquisition of the data, or to the analysis and interpretation of the data. All authors have made a substantial contribution to drafting the article or reviewing it critically. All authors have given final approval of this version of the article to be published.</p></sec></ack><ref-list id="dom13104-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13104-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="dom13104-cit-0002">
<collab collab-type="authors">US Food and Drugs Administration</collab>
. Metformin hydrochloride tablets. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf">http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf</ext-link>. Accessed February 6, 2017.</mixed-citation></ref><ref id="dom13104-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="dom13104-cit-0003">
<collab collab-type="authors">US Food and Drug Administration</collab>
. Drugs@FDA: FDA approved drug products. <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&#x00026;ApplNo=021202">http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&#x00026;ApplNo=021202</ext-link>. Accessed January 19, 2017.</mixed-citation></ref><ref id="dom13104-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="dom13104-cit-0004">
<collab collab-type="authors">European Medicines Agency</collab>
. Annex I. List of nationally authorised medicinal products. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Metformin_31/WC500201027.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Metformin_31/WC500201027.pdf</ext-link>. Accessed January 19, 2017.</mixed-citation></ref><ref id="dom13104-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom13104-cit-0005">
<string-name>
<surname>Bailey</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Turner</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Metformin</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>334</volume>:<fpage>574</fpage>&#x02013;<lpage>579</lpage>.<pub-id pub-id-type="pmid">8569826</pub-id></mixed-citation></ref><ref id="dom13104-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom13104-cit-0006">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes &#x02010; 2017: 8. Pharmacologic approaches to glycemic treatment</article-title>. <source>Diabetes Care</source>. <year>2017</year>;<volume>40</volume>:<fpage>S64</fpage>&#x02013;<lpage>S74</lpage>.<pub-id pub-id-type="pmid">27979895</pub-id></mixed-citation></ref><ref id="dom13104-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="dom13104-cit-0007">
<collab collab-type="authors">Food and Drug Administration</collab>
. New drug application. Bristol&#x02010;Myers Squibb: NDA 20&#x02010;357/S&#x02010;031 and NDA 21&#x02010;202/S&#x02010;016. Glucophage&#x000ae; (metformin hydrochloride tablets) and Glucophage&#x000ae; XR (metformin hydrochloride extended&#x02010;release tablets). <ext-link ext-link-type="uri" xlink:href="http://packageinserts.bms.com/pi/pi_glucophage.pdf">http://packageinserts.bms.com/pi/pi_glucophage.pdf</ext-link>. Accessed December 19, 2016.</mixed-citation></ref><ref id="dom13104-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13104-cit-0008">
<string-name>
<surname>Timmins</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Donahue</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meeker</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Marathe</surname>
<given-names>P</given-names>
</string-name>. <article-title>Steady&#x02010;state pharmacokinetics of a novel extended&#x02010;release metformin formulation</article-title>. <source>Clin Pharmacokinet</source>. <year>2005</year>;<volume>44</volume>:<fpage>721</fpage>&#x02013;<lpage>729</lpage>.<pub-id pub-id-type="pmid">15966755</pub-id></mixed-citation></ref><ref id="dom13104-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13104-cit-0009">
<string-name>
<surname>DeFronzo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>AM</given-names>
</string-name>. <article-title>The Multicenter Metformin Study Group. Efficacy of metformin in patients with non&#x02010;insulin&#x02010;dependent diabetes mellitus</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>:<fpage>541</fpage>&#x02013;<lpage>549</lpage>.<pub-id pub-id-type="pmid">7623902</pub-id></mixed-citation></ref><ref id="dom13104-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13104-cit-0010">
<string-name>
<surname>Fujioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Brazg</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Raz</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Efficacy, dose&#x02013;response relationship and safety of once&#x02010;daily extended&#x02010;release metformin (Glucophage&#x000ae; XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double&#x02010;blind, placebo&#x02010;controlled studies</article-title>. <source>Diabetes Obes Metab</source>. <year>2005</year>;<volume>7</volume>:<fpage>28</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">15642073</pub-id></mixed-citation></ref><ref id="dom13104-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13104-cit-0011">
<string-name>
<surname>Donnelly</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Pearson</surname>
<given-names>ER</given-names>
</string-name>. <article-title>Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population&#x02010;based study</article-title>. <source>Diabetes Obes Metab</source>. <year>2009</year>;<volume>11</volume>:<fpage>338</fpage>&#x02013;<lpage>342</lpage>.<pub-id pub-id-type="pmid">19267712</pub-id></mixed-citation></ref><ref id="dom13104-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13104-cit-0012">
<string-name>
<surname>Gao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>The metabolic effects of once daily extended&#x02010;release metformin in patients with type 2 diabetes: a multicentre study</article-title>. <source>Int J Clin Pract</source>. <year>2008</year>;<volume>62</volume>:<fpage>695</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">18412932</pub-id></mixed-citation></ref><ref id="dom13104-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13104-cit-0013">
<string-name>
<surname>Schwartz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Berner</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cramer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chiang</surname>
<given-names>YK</given-names>
</string-name>, <string-name>
<surname>Lewin</surname>
<given-names>A</given-names>
</string-name>. <article-title>Efficacy, tolerability, and safety of a novel once&#x02010;daily extended&#x02010;release metformin in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>:<fpage>759</fpage>&#x02013;<lpage>764</lpage>.<pub-id pub-id-type="pmid">16567811</pub-id></mixed-citation></ref><ref id="dom13104-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13104-cit-0014">
<string-name>
<surname>Levy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cobas</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Gomes</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Assessment of efficacy and tolerability of once&#x02010;daily extended release metformin in patients with type 2 diabetes mellitus</article-title>. <source>Diabetol Metab Syndr</source>. <year>2010</year>;<volume>2</volume>:<lpage>16</lpage>.</mixed-citation></ref><ref id="dom13104-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom13104-cit-0015">
<string-name>
<surname>Tsiatis</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Davidian</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>X</given-names>
</string-name>. <article-title>Covariate adjustment for two&#x02010;sample treatment comparisons in randomized clinical trials: a principled yet flexible approach</article-title>. <source>Stat Med</source>. <year>2008</year>;<volume>27</volume>:<fpage>4658</fpage>&#x02013;<lpage>4677</lpage>.<pub-id pub-id-type="pmid">17960577</pub-id></mixed-citation></ref><ref id="dom13104-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13104-cit-0016">
<string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsiatis</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Davidian</surname>
<given-names>M</given-names>
</string-name>. <article-title>Improving efficiency of inferences in randomized clinical trials using auxiliary covariates</article-title>. <source>Biometrics</source>. <year>2008</year>;<volume>64</volume>:<fpage>707</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">18190618</pub-id></mixed-citation></ref></ref-list></back></article>